Log in

OTCMKTS:BIOVF - Swedish Orphan Biovitrum AB (publ) Stock Price, Forecast & News

0.00 (0.00 %)
(As of 12/4/2019)
Today's Range
Now: $16.49
50-Day Range
MA: $16.43
52-Week Range
Now: $16.49
Volume650 shs
Average Volume118 shs
Market CapitalizationN/A
P/E Ratio16.01
Dividend YieldN/A
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; Gamifan for treating hemophagocytic lymphohistiocytosis; and Kineret for the treatment of rheumatoid arthritis. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Sanofi for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual Sales$1.05 billion


Net Income$278.29 million


Next Earnings Date2/19/2020 (Estimated)
OptionableNot Optionable

Receive BIOVF News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOVF and its competitors with MarketBeat's FREE daily newsletter.

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Frequently Asked Questions

What is Swedish Orphan Biovitrum AB (publ)'s stock symbol?

Swedish Orphan Biovitrum AB (publ) trades on the OTCMKTS under the ticker symbol "BIOVF."

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) announced its earnings results on Thursday, October, 31st. The company reported $0.19 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.24 by $0.05. The business had revenue of $305.65 million for the quarter, compared to analysts' expectations of $294.08 million. Swedish Orphan Biovitrum AB (publ) had a return on equity of 20.24% and a net margin of 21.36%. View Swedish Orphan Biovitrum AB (publ)'s Earnings History.

When is Swedish Orphan Biovitrum AB (publ)'s next earnings date?

Swedish Orphan Biovitrum AB (publ) is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Swedish Orphan Biovitrum AB (publ).

What is the consensus analysts' recommendation for Swedish Orphan Biovitrum AB (publ)?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Swedish Orphan Biovitrum AB (publ).

Has Swedish Orphan Biovitrum AB (publ) been receiving favorable news coverage?

Headlines about BIOVF stock have trended positive on Saturday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Swedish Orphan Biovitrum AB (publ) earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Swedish Orphan Biovitrum AB (publ).

Who are some of Swedish Orphan Biovitrum AB (publ)'s key competitors?

What other stocks do shareholders of Swedish Orphan Biovitrum AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Swedish Orphan Biovitrum AB (publ) investors own include SWEDISH ORPHAN/S (SWTUY), Consort Medical (CSRT), Arix Bioscience (ARIX), Allergy Therapeutics (AGY), Sartorius (SRT), Siemens Healthineers (SHL), STADA Arzneimit/AKT o.N. (SAZ), Gerresheimer (GXI), Evotec (EVT) and Neptune Technologies & Bioressources (NTB).

Who are Swedish Orphan Biovitrum AB (publ)'s key executives?

Swedish Orphan Biovitrum AB (publ)'s management team includes the folowing people:
  • Dr. Guido Oelkers, CEO & Pres (Age 54)
  • Mr. Henrik Stenqvist, Chief Financial Officer (Age 52)
  • Ms. Anne Marie de Jonge Schuermans, Head of Technical Operations (Age 47)
  • Ms. Paula Treutiger, Head of Communications & Investor Relations (Age 52)
  • Mr. Torbjörn Hallberg, Gen. Counsel & Head of Legal Affairs (Age 50)

How do I buy shares of Swedish Orphan Biovitrum AB (publ)?

Shares of BIOVF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Swedish Orphan Biovitrum AB (publ)'s stock price today?

One share of BIOVF stock can currently be purchased for approximately $16.49.

What is Swedish Orphan Biovitrum AB (publ)'s official website?

The official website for Swedish Orphan Biovitrum AB (publ) is http://www.sobi.com/.

How can I contact Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ)'s mailing address is Tomtebodavagen 23 A Solna, Stockholm V7, SE-112 76. The company can be reached via phone at 46-8697-2000 or via email at [email protected]

MarketBeat Community Rating for Swedish Orphan Biovitrum AB (publ) (OTCMKTS BIOVF)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  12 (Vote Underperform)
Total Votes:  18
MarketBeat's community ratings are surveys of what our community members think about Swedish Orphan Biovitrum AB (publ) and other stocks. Vote "Outperform" if you believe BIOVF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOVF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel